Valuation: GenFleet Therapeutics (Shanghai) Inc.

Market Cap 7.07B 8.33B 1.06B 951M 875M 793M 1.48B 101B 1.51B 10.44B 4.19B 53.05B 3.99B 3.9B 167B P/E 2026 *
-9.76x
P/E 2027 * -35.9x
Enterprise Value 5.11B 6.02B 768M 688M 632M 573M 1.07B 72.89B 1.09B 7.54B 3.03B 38.34B 2.88B 2.82B 121B EV / Sales 2026 *
57.8x
EV / Sales 2027 * 19.7x
Free-Float
73.88%
Yield 2026 *
-
Yield 2027 * -
10-27 GenFleet Therapeutics Inc. Presents Initial Clinical Readout Of GFH276 At 2026 ESMO Annual Meeting CI
10-15 GenFleet's Oral Cancer Drug Enters Phase III Testing in China; Shares Up 3% MT
10-15 GenFleet Therapeutics Inc. Reports Positive Progress For GFH375/VS-7375 Across Multiple Clinical Studies In China And Abroad CI
09-28 GenFleet Therapeutics Shanghai Inc Receives Third Breakthrough Therapy Designation For GFH375 CI
09-24 Genfleet Therapeutics Inc. Announces Resignation of Tao Sha as Non-Executive Director, Effective September 24, 2026 CI
09-22 GenFleet Therapeutics Inc. Clinical Program Evaluating GFH375 Combined with Cetuximab Places on the Proposed Breakthrough Therapy Designation List by China?s National Medical Products Administration CI
09-18 267,740,630 H Shares of GenFleet Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2026. CI
09-16 GenFleet Therapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
09-15 GenFleet Presents Updated Lung Cancer Therapy Data at Korean Medical Conference MT
09-02 GenFleet Therapeutics Inc. commences an Equity Buyback Plan for 37,036,663 shares, representing 10% of its issued share capital, under the authorization approved on May 11, 2026. CI
08-26 GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial MT
08-26 Genfleet Therapeutics Inc. Advances Gfh375, Oral Kras G12d Inhibitor, into Phase Ii Study for First-Line Treatment of Non-Small Cell Lung Cancer CI
08-20 GenFleet Therapeutics Starts Phase 2 Study of Two Novel Pancreatic Cancer Combinations; Shares Rise 12% MT
1 day-9.86%
1 week-24.95%
Current month-31.82%
1 month-31.82%
3 months-15.98%
6 months-47.84%
Current year-5.38%
1 week 22.5
Extreme 22.5
30.74
1 month 22.5
Extreme 22.5
33.42
Current year 19.6
Extreme 19.6
52.9
1 year 19.6
Extreme 19.6
52.9
3 years 19.6
Extreme 19.6
52.9
5 years 19.6
Extreme 19.6
52.9
10 years 19.6
Extreme 19.6
52.9
Manager TitleAgeSince
Chief Executive Officer 53 22/08/2017
Chief Tech/Sci/R&D Officer - 01/11/2020
Corporate Secretary 47 24/03/2026
Director TitleAgeSince
Director/Board Member 53 22/08/2017
Chairman 41 22/08/2017
Director/Board Member 47 -
Change 5-day change 1-year change 3-year change Capi.($)
-9.86%-24.95%-15.35% - 1.06B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.68%+4.29%+41.54%+206.32% 39.54B
Weighted average by Cap. +0.15%+5.36%+48.33%+186.13%

Financials

2026 *2027 *
Net sales 88.32M 104M 13.27M 11.88M 10.93M 9.91M 18.52M 1.26B 18.86M 130M 52.33M 663M 49.8M 48.74M 2.09B 284M 335M 42.64M 38.19M 35.13M 31.83M 59.49M 4.05B 60.61M 419M 168M 2.13B 160M 157M 6.72B
Net income -725M -854M -109M -97.51M -89.69M -81.27M -152M -10.34B -155M -1.07B -429M -5.44B -409M -400M -17.15B -198M -234M -29.82M -26.71M -24.57M -22.26M -41.61M -2.83B -42.38M -293M -118M -1.49B -112M -110M -4.7B
Net Debt -1.96B -2.31B -295M -264M -243M -220M -411M -27.97B -419M -2.89B -1.16B -14.71B -1.11B -1.08B -46.4B -1.47B -1.73B -220M -197M -181M -164M -307M -20.91B -313M -2.16B -868M -11B -826M -809M -34.68B
Projected Income Statement - Annual - GenFleet Therapeutics (Shanghai) Inc.
Logo GenFleet Therapeutics (Shanghai) Inc.
GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.
Employees
159
Date Price Change Volume
30/10/26 HK$22.50 -9.86% 4,361,400
29/10/26 HK$24.96 -7.07% 4,271,520
28/10/26 HK$26.86 -1.25% 2,506,200
27/10/26 HK$27.20 -3.13% 1,423,764
26/10/26 HK$28.08 -6.34% 3,952,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GenFleet Therapeutics (Shanghai) Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.09CNY
Average target price
43.43CNY
Spread / Average Target
+127.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GenFleet Therapeutics (Shanghai) Inc.
  1. Stock Market
  2. Stocks
  3. 2595 Stock